(CMR) According to COVID-19 vaccine manufacturer, AstraZeneca, its product is still highly effective despite admitting that a dosing error was made during its test trials.
Following the release of preliminary data from the trial, the vaccine manufacturer admitted that some 2,741 people who participated in the study only received a half dose of the vaccine.
Interesting to note, among the group of volunteers that got a lower dose of the vaccine, these individuals seemed to be better protected than the volunteers who got two full doses.
According to AstraZeneca the vaccine appeared to be 90% effective in the low dose group.
In the group that got two full doses, the vaccine appeared to be 62% effective.
However the small size of the low dose group makes it impossible to say with certainty anything about the effectiveness of the vaccine, with some researchers noting that it could simply be a “statistical quirk”.
According to the Oxford University who worked in collaboration with AstraZeneca the findings and the error were discussed with the regulators.
In September 2020, AstraZeneca paused clinical trials after a patient fell ill.
AstraZeneca is among vaccine manufacturers like Pfizer and Moderna who announced that they too had developed COVID-19vaccines, boasting 95 percent effectiveness.